High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine. These are the findings of a study published today in The New England Journal of Medicine, led by researchers at Karolinska Institutet and Danderyd Hospital in Sweden.
Mucosal antibodies in the airways protect against omicron infection
September 14, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022